Download PDF

Published: 15 November 2017


In this issue:

  • YEARS for managing suspected PE 
  • Validating the HERDOO2 rule 
  • Occult cancer screening in unprovoked VTE 
  • PE and DVT risk increased in asthmatics 
  • COPD does not increase recurrent VTE risk 
  • IVC filters for preventing PE 
  • Rivaroxaban vs. aspirin for extended VTE treatment 
  • VTE management practices in Australia 
  • Review of exercise benefits in pulmonary hypertension 
  • Upfront combination therapy reduces RV volumes in PAH 
  • Clinical phenotypes and outcomes of PVOD 
  • Long-term outcomes of dasatinib-induced PAH 
  • Risk stratification